[{"address1": "Uppsalalaan 17", "address2": "3rd & 4th floor", "city": "Utrecht", "zip": "3584 CT", "country": "Netherlands", "phone": "31 30 253 8800", "website": "https://www.merus.nl", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.", "fullTimeEmployees": 172, "maxAge": 86400, "priceHint": 2, "previousClose": 53.94, "open": 54.04, "dayLow": 53.01, "dayHigh": 54.9, "regularMarketPreviousClose": 53.94, "regularMarketOpen": 54.04, "regularMarketDayLow": 53.01, "regularMarketDayHigh": 54.9, "beta": 1.099, "forwardPE": -16.719513, "volume": 616080, "regularMarketVolume": 616080, "averageVolume": 959264, "averageVolume10days": 843100, "averageDailyVolume10Day": 843100, "bid": 54.76, "ask": 54.96, "bidSize": 100, "askSize": 200, "marketCap": 3694570752, "fiftyTwoWeekLow": 19.805, "fiftyTwoWeekHigh": 61.61, "priceToSalesTrailing12Months": 96.37089, "fiftyDayAverage": 48.1628, "twoHundredDayAverage": 35.6918, "currency": "USD", "enterpriseValue": 2892456192, "floatShares": 47290429, "sharesOutstanding": 67370000, "sharesShort": 3482923, "sharesShortPriorMonth": 3290345, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.059299998, "heldPercentInsiders": 0.06511, "heldPercentInstitutions": 0.79847, "shortRatio": 4.86, "shortPercentOfFloat": 0.059699997, "impliedSharesOutstanding": 67370000, "bookValue": 5.954, "priceToBook": 9.210615, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -149654000, "trailingEps": -2.73, "forwardEps": -3.28, "pegRatio": 2.24, "enterpriseToRevenue": 75.448, "enterpriseToEbitda": -17.632, "52WeekChange": 1.1761904, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "MRUS", "underlyingSymbol": "MRUS", "shortName": "Merus N.V.", "longName": "Merus N.V.", "firstTradeDateEpochUtc": 1463664600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "42321671-9233-3f73-a2ee-487472589127", "messageBoardId": "finmb_24929296", "gmtOffSetMilliseconds": -14400000, "currentPrice": 54.84, "targetHighPrice": 100.0, "targetLowPrice": 67.0, "targetMeanPrice": 85.5, "targetMedianPrice": 88.0, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 337496000, "totalCashPerShare": 5.751, "ebitda": -164044992, "totalDebt": 11527000, "quickRatio": 5.07, "currentRatio": 5.227, "totalRevenue": 38337000, "debtToEquity": 3.299, "revenuePerShare": 0.703, "returnOnAssets": -0.24892999, "returnOnEquity": -0.52791, "freeCashflow": -129249504, "operatingCashflow": -149852000, "revenueGrowth": -0.416, "grossMargins": -2.766, "operatingMargins": -5.9334497, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]